Imida Tablet

Imida tablet is indicated for the treatment of overactive bladder with symptoms of urinary urgency, urinary frequency, and urge urinary incontinence.

Imidafenacin is an anti-muscarinic agent. Imidafenacin exerts its effects by selectively blocking muscarinic receptors, specifically the M3 subtype, which are predominantly found in the detrusor muscle of the bladder. Muscarinic receptors are a type of acetylcholine receptor that play a critical role in the contraction of smooth muscles, including those in the bladder. When acetylcholine binds to these receptors, it triggers a cascade of events that result in muscle contraction, facilitating the process of urination.

The usual oral dose of Imidafenacin for adults is 0.1 mg twice daily, after the meal. If necessary, the dosage may be increased up to 0.2 mg twice daily (0.4 mg/day) or as directed by the physician. The safety and effectiveness of Imidafenacin in paediatric patients have not been established.

CYP3A4 inhibiting agents such as Itraconazole, Ketoconazole, Erythromycin, and Clarithromycin have the possibility of increased
blood serum Imida concentration, which in turn increases the risk of overdose. Anticholinergic effects of Imida may escalate in case of concomitant administration of anti-histamins, tricyclic anti-depressants, phenothiazines and monoamino oxidase inhibitors may increase the risk of side effects.

Imidafenacin tablets are contraindicated in patients who have certain medical conditions such as patients with urinary retention, those with an obstruction in the pyloric region/ duodenum /intestine or those with paralytic ileus. Additionally, patients with decreased gastrointestinal motility, muscle tone, narrow-angle glaucoma, or myasthenia gravis should not use this medication. Furthermore, it is contraindicated in patients with known hypersensitivity to any of the components of these tablets.

Clinically significant adverse reactions to Imida are acute glaucoma, urinary retention, and hepatic dysfunction. The most common adverse effects observed with Imida are dry mouth and constipation.

Product safety is not established during pregnancy and lactation.

Careful administration should be needed for the following patients- Patients with dysuria, arrhythmia, hepatic dysfunction, renal
dysfunction, dementia or cognitive dysfunction, cerebrovascular disorder, ulcerative colitis and hyperthyroidism.

Symptoms following acute overdosages of Imida have shown urinary retention, mydriasis, excitement, tachycardia etc.

BPH/ Urinary retention/ Urinary incontinence

Store below 25°C, away from light and in a dry place. Keep all medicines out of the reach of children.